Evaluation of Pain Sensitization in Rheumatoid Arthritis: Analysis on a Cohort of Tofacitinib Treated Patients

Inclusion criteria

• Patients aged over 18 year-old ;
• Diagnosis of RA according to the ACR/EULAR 2010 classification criteria ;
• Active rheumatoid arthritis defined by a Disease Activity Score (DAS28) > 3.2 at inclusion ;
• Patient eligible for tofacitinib treatment in agreement with European treatment labelling and French recommendation for RA treatment ;
• Oral prednisone intake is allowed until 10 mg, stable for at least 1 week at study entry ;
• Starting tofacitinib treatment for an active RA defined by a DAS28-ESR > 3.2 ;
• Affiliated person or beneficiary of a social security scheme ;
• Having signed an informed consent (at the latest on the day of inclusion and before any examination required by research).

Exclusion criteria

• Diagnosis of a systemic autoimmune disease other than RA ;
• Peripheral neuropathy ;
• Centrally-acting pain medications use within 3 months of enrolment (amitriptyline, gabapentin, duloxetine), or during the study ;
• Any opioid use within 1 month of enrolment or during the study ;
• Corticosteroid treatment over 10 mg of prednisone or equivalent ;
• Patient who present contraindications to tofacitinib treatment ;
• Patient presenting with a history of active tuberculosis or chronic infectious disease with a need of regular use of antibiotic ;
• Patients with active bacterial or viral infection, or presenting with an episode of infection that required treatment with antibiotics within 30 days prior to screening ;
• Patient presenting with a history of lymphoma or leukaemia or other malignancy besides non-melanoma skin cancer within 5 years ;
• Patient presenting with any uncontrolled medical condition ;
• Pregnancy or breast-feeding ;
• Patient unable to understand and follow recommendations or unable to perform self-evaluation ;
• Patient who refuse to participate to the study.